Payment overview · 2025
General Payments
$199.26
9 reported records · 7 companies
Healthcare provider profile · identity verified
Muhammad A. Shaikh, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LAKE CHARLES, LA · NPI 1396705752
Verified facts
What the public records show
CMS Open Payments records show Muhammad A. Shaikh, M.D. received $199.26 in general payments during 2025 across 9 reported records.
Exact Sciences Corporation accounted for 28.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Mounjaro by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $57.51 | 28.9% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $35.74 | 17.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $26.97 | 13.5% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $23.06 | 11.6% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $21.63 | 10.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.00 | 10.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.35 | 7.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $199.26 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $41.85 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $35.74 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $26.97 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $23.06 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 88 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
117 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
230 | 55 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
88 | 16 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 915 | 261 |
| Atorvastatin Calcium | Atorvastatin Calcium | 796 | 230 |
| Gabapentin | Gabapentin | 498 | 155 |
| Lisinopril | Lisinopril | 443 | 123 |
| Pantoprazole Sodium | Pantoprazole Sodium | 375 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 358 | 80 |
| Metformin Hcl | Metformin Hcl | 295 | 89 |
| Losartan Potassium | Losartan Potassium | 292 | 92 |
| Hydrochlorothiazide | Hydrochlorothiazide | 265 | 78 |
| Furosemide | Furosemide | 264 | 82 |
| Metoprolol Tartrate | Metoprolol Tartrate | 251 | 75 |
| Potassium Chloride | Potassium Chloride | 245 | 78 |
| Jardiance | Empagliflozin | 230 | 55 |
| Carvedilol | Carvedilol | 189 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 184 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 182 | 59 |
| Glimepiride | Glimepiride | 178 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 169 | 56 |
| Ozempic | Semaglutide | 162 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 133 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 119 | 39 |
| Farxiga | Dapagliflozin Propanediol | 117 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 116 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 110 | 35 |
| Sertraline Hcl | Sertraline Hcl | 108 | 30 |
| Omeprazole | Omeprazole | 103 | 33 |
| Amitriptyline Hcl | Amitriptyline Hcl | 97 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 90 | 33 |
| Meloxicam | Meloxicam | 88 | 29 |
| Mounjaro | Tirzepatide | 88 | 16 |
| Trazodone Hcl | Trazodone Hcl | 88 | 29 |
| Allopurinol | Allopurinol | 80 | 25 |
| Atenolol | Atenolol | 80 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 75 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 72 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 70 | 19 |
| Eliquis | Apixaban | 70 | 19 |
| Januvia | Sitagliptin Phosphate | 69 | 17 |
| Ezetimibe | Ezetimibe | 66 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 24 |
| Famotidine | Famotidine | 59 | 16 |
| Nifedipine Er | Nifedipine | 58 | 14 |
| Montelukast Sodium | Montelukast Sodium | 57 | 14 |
| Novolog Flexpen | Insulin Aspart | 56 | 13 |
| Clonidine Hcl | Clonidine Hcl | 55 | 19 |
| Pregabalin | Pregabalin | 54 | 11 |
| Propranolol Hcl | Propranolol Hcl | 52 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 50 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 12 |
| Buspirone Hcl | Buspirone Hcl | 48 | 11 |
| Metformin Hcl Er | Metformin Hcl | 45 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 16 |
| Irbesartan | Irbesartan | 43 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 16 |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Spironolactone | Spironolactone | 39 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 38 | 13 |
| Simvastatin | Simvastatin | 35 | suppressed |
| Valsartan | Valsartan | 35 | suppressed |
| Baclofen | Baclofen | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 31 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 31 | 12 |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 28 | 12 |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 14 |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $199.26 · 9 records | Exact Sciences Corporation | Azstarys, BREZTRI, CAPLYTA, Cologuard Collection Kit, INSPIRE, MOUNJARO, TZIELD, The Cologuard Plus Collection Kit, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error